Cargando…

Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients

BACKGROUND: Immune escape has recently emerged as one of the barriers to the efficacy of immunotherapy in lung adenocarcinoma (LUAD). However, the clinical significance and function of immune escape markers in LUAD have largely not been clarified. METHODS: In this study, we constructed a stable and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ting, Huang, Lin, Zhou, Jie, Li, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018159/
https://www.ncbi.nlm.nih.gov/pubmed/36936970
http://dx.doi.org/10.3389/fimmu.2023.1131768
_version_ 1784907752791867392
author Wang, Ting
Huang, Lin
Zhou, Jie
Li, Lu
author_facet Wang, Ting
Huang, Lin
Zhou, Jie
Li, Lu
author_sort Wang, Ting
collection PubMed
description BACKGROUND: Immune escape has recently emerged as one of the barriers to the efficacy of immunotherapy in lung adenocarcinoma (LUAD). However, the clinical significance and function of immune escape markers in LUAD have largely not been clarified. METHODS: In this study, we constructed a stable and accurate immune escape score (IERS) by systematically integrating 10 machine learning algorithms. We further investigated the clinical significance, functional status, TME interactions, and genomic alterations of different IERS subtypes to explore potential mechanisms. In addition, we validated the most important variable in the model through cellular experiments. RESULTS: The IERS is an independent risk factor for overall survival, superior to traditional clinical variables and published molecular signatures. IERS-based risk stratification can be well applied to LUAD patients. In addition, high IERS is associated with stronger tumor proliferation and immunosuppression. Low IERS exhibited abundant lymphocyte infiltration and active immune activity. Finally, high IERS is more sensitive to first-line chemotherapy for LUAD, while low IERS is more sensitive to immunotherapy. CONCLUSION: In conclusion, IERS may serve as a promising clinical tool to improve risk stratification and clinical management of individual LUAD patients and may enhance the understanding of immune escape.
format Online
Article
Text
id pubmed-10018159
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100181592023-03-17 Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients Wang, Ting Huang, Lin Zhou, Jie Li, Lu Front Immunol Immunology BACKGROUND: Immune escape has recently emerged as one of the barriers to the efficacy of immunotherapy in lung adenocarcinoma (LUAD). However, the clinical significance and function of immune escape markers in LUAD have largely not been clarified. METHODS: In this study, we constructed a stable and accurate immune escape score (IERS) by systematically integrating 10 machine learning algorithms. We further investigated the clinical significance, functional status, TME interactions, and genomic alterations of different IERS subtypes to explore potential mechanisms. In addition, we validated the most important variable in the model through cellular experiments. RESULTS: The IERS is an independent risk factor for overall survival, superior to traditional clinical variables and published molecular signatures. IERS-based risk stratification can be well applied to LUAD patients. In addition, high IERS is associated with stronger tumor proliferation and immunosuppression. Low IERS exhibited abundant lymphocyte infiltration and active immune activity. Finally, high IERS is more sensitive to first-line chemotherapy for LUAD, while low IERS is more sensitive to immunotherapy. CONCLUSION: In conclusion, IERS may serve as a promising clinical tool to improve risk stratification and clinical management of individual LUAD patients and may enhance the understanding of immune escape. Frontiers Media S.A. 2023-03-02 /pmc/articles/PMC10018159/ /pubmed/36936970 http://dx.doi.org/10.3389/fimmu.2023.1131768 Text en Copyright © 2023 Wang, Huang, Zhou and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Ting
Huang, Lin
Zhou, Jie
Li, Lu
Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
title Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
title_full Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
title_fullStr Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
title_full_unstemmed Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
title_short Systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
title_sort systematic integration of machine learning algorithms to develop immune escape-related signatures to improve clinical outcomes in lung adenocarcinoma patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018159/
https://www.ncbi.nlm.nih.gov/pubmed/36936970
http://dx.doi.org/10.3389/fimmu.2023.1131768
work_keys_str_mv AT wangting systematicintegrationofmachinelearningalgorithmstodevelopimmuneescaperelatedsignaturestoimproveclinicaloutcomesinlungadenocarcinomapatients
AT huanglin systematicintegrationofmachinelearningalgorithmstodevelopimmuneescaperelatedsignaturestoimproveclinicaloutcomesinlungadenocarcinomapatients
AT zhoujie systematicintegrationofmachinelearningalgorithmstodevelopimmuneescaperelatedsignaturestoimproveclinicaloutcomesinlungadenocarcinomapatients
AT lilu systematicintegrationofmachinelearningalgorithmstodevelopimmuneescaperelatedsignaturestoimproveclinicaloutcomesinlungadenocarcinomapatients